The Streptavidin/Biotinylated DNA/Protein Bound Complex Protocol for Determining the Association of c‐JUN Protein with NANOG Promoter

Elsayed E. Ibrahim1, Roya Babaei‐Jadidi1, Abdolrahman S. Nateri1

1 Nottingham Digestive Diseases Centre, School of Clinical Sciences, University of Nottingham, Nottingham, Nottingham, United Kingdom
Publication Name:  Current Protocols in Stem Cell Biology
Unit Number:  Unit 1B.10
DOI:  10.1002/9780470151808.sc01b10s25
Online Posting Date:  May, 2013
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Chromatin immunoprecipitation (ChIP) is a widely used and pre‐eminent technique for detecting the association of an individual protein or a particular protein complex with its specific DNA sequence(s) in vivo. Herein we introduce a novel and simple biotinylated‐oligonucleotide‐mediated ChIP method for testing specific binding of the c‐JUN protein to the M1‐DNA‐regulatory element in the NANOG promoter. We prepared a 260‐bp DNA PCR amplicon containing −300 bp to −59 bp, relative to the transcriptional start site of the human NANOG gene, which was transfected into mouse embryonic fibroblasts (MEF) containing wild‐type (cjun+/+) or knockout c‐jun (c‐jun−/−) alleles. Whole cells that were cross‐linked using formaldehyde and protein‐DNA interactions were immunoprecipitated using streptavidin‐coupled Dynabeads. Protein‐DNA cross‐links were reversed during incubation at 95°C, and protein samples were visualized using SDS‐PAGE electrophoresis and western blotting. This streptavidin/biotinylated DNA/protein‐bound complex protocol can be used for detecting the interactions between multiple transcription factors and their DNA binding sites. Curr. Protoc. Stem Cell Biol. 25:1B.10.1‐1B.10.13. © 2013 by John Wiley & Sons, Inc.

Keywords: ChIP; c‐JUN; NANOG; streptavidin/biotin

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Basic Protocol 1: Chromatin Immunoprecipitation (ChIP): Cell Preparation and Cross‐Linking
  • Basic Protocol 2: Immunoprecipitation (IP) and Reversal Cross‐Linking
  • Support Protocol 1: Designing Oligonucleotides and NANOG Promoter Amplification
  • Support Protocol 2: Detection of the NANOG Promoter–Associated Protein (e.g., c‐JUN) Using Western Blotting
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Chromatin Immunoprecipitation (ChIP): Cell Preparation and Cross‐Linking

  Materials
  • Mouse embryonic fibroblasts (MEFs; c‐jun+/+ and c‐jun−/−; gift from Dr. Axel Behrens, Cancer Research UK–London Research Institute)
  • 1% (w/v) gelatin (Sigma, cat. no. G7765)
  • Phosphate‐buffered saline (PBS; Sigma, cat. no. P4417; one tablet dissolved in 200 ml of deionized H 2O yields 0.01 M phosphate buffer/0.0027 M potassium chloride/0.137 M sodium chloride, pH 7.4, at 25°C)
  • Dulbecco's modified Eagle medium (DMEM; Sigma, cat. no. D5671)
  • Complete DMEM growth medium (see recipe)
  • NANOG‐promoter PCR product ( protocol 3)
  • Opti‐MEM I reduced‐serum medium (Invitrogen, cat. no. 31985‐047)
  • Lipofectamine 2000 reagent (Invitrogen, cat. no. 11668‐019)
  • 11% (v/v) formaldehyde solution (see recipe)2.5 M glycine (Sigma, cat. no. G8898)
  • RIPA lysis buffer (see recipe)
  • 10‐cm tissue culture plates
  • Rubber scraper
  • Centrifuge
NOTE: All incubations are performed in a 37°C, 5% CO 2 humidified incubator, unless otherwise noted.NOTE: All reagents and equipment coming into contact with living cells must be sterile, and aseptic technique should be used accordingly.

Basic Protocol 2: Immunoprecipitation (IP) and Reversal Cross‐Linking

  Materials
  • Dynabeads M‐280 Streptavidin (Invitrogen, cat. no. 112.05D)
  • Binding & washing (B & W) buffer (see recipe)
  • DNA‐protein extract ( protocol 1)
  • Dulbecco's phosphate‐buffered saline (DPBS; Sigma, cat. no. D8662) containing 0.1% (v/v) NP‐40 and 1× fresh protease inhibitor cocktail (Sigma, cat. no. P2714)
  • 5× loading buffer (see recipe)
  • DynaMag‐2 magnet (Invitrogen, cat. no. 123‐21D)
  • Shaking thermomixer

Support Protocol 1: Designing Oligonucleotides and NANOG Promoter Amplification

  Materials
  • Biotinylated and non‐biotinylated oligonucleotides corresponding to NANOG promoter (nucleotides –300 to –59; see above)
  • Nuclease‐free H 2O
  • Human embryonic stem cells (hESCs; unit 1.5)
  • Phosphate‐buffered saline (PBS; Sigma, cat. no. D8537)
  • DirectPCR lysis reagent (Viagen Biotech, cat. no. 402E, http://www.viagenbiotech.com/)
  • Proteinase K (Sigma, cat. no. P6556)
  • Extracted genomic template DNA
  • 10× PCR reaction buffer (Qiagen, cat. no. 201223)
  • 0.25 mM dNTP mix (Qiagen, cat. no. 201913)
  • 5 U/µl Taq DNA polymerase (Qiagen, cat. no. 201205)
  • Agarose powder (Eurogenetic, cat. no. EP‐0010‐05)
  • Tris‐acetate‐EDTA (TAE) buffer, pH 8.0 (Sigma, cat. no. T9650)
  • Ethidium bromide (EtBr; Sigma, cat. no. E1385)
  • Illustra GFX PCR DNA and Gel Band purification kit (GE Healthcare, cat. no. 28‐9034‐70)
  • Shaking Thermomixer (Fisher, cat. no. BLD‐455‐010C)
  • 0.2‐ml PCR tubes (Qiagen)
  • Thermal cycler (Applied Biosystems)

Support Protocol 2: Detection of the NANOG Promoter–Associated Protein (e.g., c‐JUN) Using Western Blotting

  Materials
  • 1× Tris/glycine/SDS (TGS) running buffer (Bio‐Rad, cat. no. 161‐0772)
  • Semi‐dry transfer buffer (see recipe)
  • Dried milk (GE Healthcare, cat. no. CPK1075)
  • Tris‐buffered saline (TBS; see recipe)
  • Tween 20 (Sigma, cat. no. 1379)
  • Primary antibody: c‐JUN antibody (from rabbit; Santa Cruz Biotechnology, cat. no. sc‐1694)
  • Secondary antibody: directed against rabbit Ig
  • Polyvinylidene difluoride (PVDF) membrane (GE Healthcare, cat. no. RPN303F)
  • Semi‐dry electrophoretic transfer cell (Bio‐Rad)
  • Platform rotator
  • ECL Advanced Western blotting detection kit (Amersham, cat. no. RPN2135)
  • FluorChem FC2 imaging system (Alpha Innotech)
  • Additional reagents and equipment for SDS‐PAGE (Gallagher, ) and protein blotting (Gallagher et al., 2008)
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
   Babaei‐Jadidi, R., Li, N., Saadeddin, A., Spencer‐Dene, B., Jandke, A., Muhammad, B., Ibrahim, E.E., Muraleedharan, R., Abuzinadah, M., Davis, H., Lewis, A., Watson, S., Behrens, A., Tomlinson, I., and Nateri, A.S. 2011. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 208:295‐312.
   Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., and Smith, A. 2003. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113:643‐655.
   Chambers, I., Silva, J., Colby, D., Nichols, J., Nijmeijer, B., Robertson, M., Vrana, J., Jones, K., Grotewold, L., and Smith, A. 2007. Nanog safeguards pluripotency and mediates germline development. Nature 450:1230‐1234.
   Collas, P. 2010. The current state of chromatin immunoprecipitation. Mol. Biotechnol. 45:87‐100.
   Dahl, J.A. and Collas, P. 2008. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat. Protocols 3:1032‐1045.
   Darr, H., Mayshar, Y., and Benvenisty, N. 2006. Overexpression of NANOG in human ES cells enables feeder‐free growth while inducing primitive ectoderm features. Development 133:1193‐1201.
   Dedon, P.C., Soults, J.A., Allis, C.D., and Gorovsky, M.A. 1991. Formaldehyde cross‐linking and immunoprecipitation demonstrate developmental changes in H1 association with transcriptionally active genes. Mol. Cell. Biol. 11:1729‐1733.
   Eberle, I., Pless, B., Braun, M., Dingermann, T., and Marschalek, R. 2010. Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells. Nucleic Acids Res. 38:5384‐5395.
   Fanelli, M., Amatori, S., Barozzi, I., and Minucci, S. 2011. Chromatin immunoprecipitation and high‐throughput sequencing from paraffin‐embedded pathology tissue. Nat. Protocols 6:1905‐1919.
   Gallagher, S.R. 2012. One‐dimensional SDS gel electrophoresis of proteins. Curr. Protoc. Mol. Biol. 97:10.2A.1–10.2A.44.
   Go, M.J., Takenaka, C., and Ohgushi, H. 2008. Forced expression of Sox2 or Nanog in human bone marrow derived mesenchymal stem cells maintains their expansion and differentiation capabilities. Exp. Cell Res. 314:1147‐1154.
   Hatano, S.Y., Tada, M., Kimura, H., Yamaguchi, S., Kono, T., Nakano, T., Suemori, H., Nakatsuji, N., and Tada, T. 2005. Pluripotential competence of cells associated with Nanog activity. Mech. Dev. 122:67‐79.
   Ibrahim, E.E., Babaei‐Jadidi, R., Saadeddin, A., Spencer‐Dene, B., Hossaini, S., Abuzinadah, M., Li, N., Fadhil, W., Ilyas, M., Bonnet, D., and Nateri, A.S. 2012. Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1‐ and TCF‐dependent mechanisms. Stem Cells 30:2076‐2087.
   Ishiguro, T., Sato, A., Ohata, H., Sakai, H., Nakagama, H., and Okamoto, K. 2011. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem. Biophys. Res. Commun. 418:199‐204.
   Lin, Y.L., Han, Z.B., Xiong, F.Y., Tian, L.Y., Wu, X.J., Xue, S.W., Zhou, Y.R., Deng, J.X., and Chen, H.X. 2011. Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol. Cell. Biochem. 351:109‐116.
   Meng, H.M., Zheng, P., Wang, X.Y., Liu, C., Sui, H.M., Wu, S.J., Zhou, J., Ding, Y.Q., and Li, J.M. 2010. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol. Ther. Feb 16;9(4).
   Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., and Yamanaka, S. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113:631‐642.
   Nateri, A.S., Spencer‐Dene, B., and Behrens, A. 2005. Interaction of phosphorylated c‐Jun with TCF4 regulates intestinal cancer development. Nature 437:281‐285.
   Niwa, H. 2007. How is pluripotency determined and maintained? Development 134:635‐646.
   Niwa, H., Ogawa, K., Shimosato, D., and Adachi, K. 2009. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 460:118‐122.
   O'Neill, L.P. and Turner, B.M. 1996. Immunoprecipitation of chromatin. Methods Enzymol. 274:189‐197.
   O'Neill, L.P. and Turner, B.M. 2003. Immunoprecipitation of native chromatin: NChIP. Methods 31:76‐82.
   Pereira, L., Yi, F., and Merrill, B.J. 2006. Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self‐renewal. Mol. Cell. Biol. 26:7479‐7491.
   Piestun, D., Kochupurakkal, B.S., Jacob‐Hirsch, J., Zeligson, S., Koudritsky, M., Domany, E., Amariglio, N., Rechavi, G., and Givol, D. 2006. Nanog transforms NIH3T3 cells and targets cell‐type restricted genes. Biochem. Biophys. Res. Commun. 343:279‐285.
   Po, A., Ferretti, E., Miele, E., De Smaele, E., Paganelli, A., Canettieri, G., Coni, S., Di Marcotullio, L., Biffoni, M., Massimi, L., Di Rocco, C., Screpanti, I., and Gulino, A. 2010. Hedgehog controls neural stem cells through p53‐independent regulation of Nanog. EMBO J. 29:2646‐2658.
   Saleh, A., Alvarez‐Venegas, R., and Avramova, Z. 2008. An efficient chromatin immunoprecipitation (ChIP) protocol for studying histone modifications in Arabidopsis plants. Nat. Protocols 3:1018‐1025.
   Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., Ma, L., Liu, J., Xu, S., Yan, X., Bie, P., Cui, Y., Bian, X.W., and Qian, C. 2012. Nanog regulates self‐renewal of cancer stem cells through the insulin‐like growth factor pathway in human hepato‐cellular carcinoma. Hepatology 56:1004‐1014.
   Silva, J., Nichols, J., Theunissen, T.W., Guo, G., van Oosten, A.L., Barrandon, O., Wray, J., Yamanaka, S., Chambers, I., and Smith, A. 2009. Nanog is the gateway to the pluripotent ground state. Cell 138:722‐737.
   Takao, Y., Yokota, T., and Koide, H. 2007. Beta‐catenin up‐regulates Nanog expression through interaction with Oct‐3/4 in embryonic stem cells. Biochem. Biophys. Res. Commun. 353:699‐705.
   Wu da, Y. and Yao, Z. 2005. Isolation and characterization of the murine Nanog gene promoter. Cell Res. 15:317‐324.
   Xu, R.H., Sampsell‐Barron, T.L., Gu, F., Root, S., Peck, R.M., Pan, G., Yu, J., Antosiewicz‐Bourget, J., Tian, S., Stewart, R., and Thomson, J.A. 2008. NANOG is a direct target of TGFbeta/activin‐mediated SMAD signaling in human ESCs. Cell Stem Cell 3:196‐206.
   Zbinden, M., Duquet, A., Lorente‐Trigos, A., Ngwabyt, S.N., Borges, I., and Ruiz i Altaba, A. 2010. NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐functional network with GLI1 and p53. EMBO J. 29:2659‐2674.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library